Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Oncology Research
|
September 28, 2019
Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres<sup>®</sup> in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres<sup>®</sup> Transarterial Chemoembolization in Liver Cancer (CTILC) Study
Junhui Sun, Guanhui Zhou, Xiaoxi Xie, et al.
Liver Cancer
|
March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Zhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
Medicine
|
March 21, 2020
Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study
Jun Luo, Jiaping Zheng, Changsheng Shi, et al.
Oncology Research
|
December 21, 2019
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres<sup>®</sup> Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study
Zhiyi Peng, Guohong Cao, Qinming Hou, et al.
Translational Cancer Research
|
February 4, 2022
Efficacy and safety of CalliSpheres<sup>®</sup> drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study
Xia Wu, Shihong Ying, Jing Huang, et al.
Frontiers in Oncology
|
August 19, 2022
A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Hong Yang, Lin Wang, Guoliang Shao, et al.
Liver Cancer
|
August 20, 2025
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Yoon Jun Kim, Philippe Merle, Richard S Finn, et al.
Liver Cancer
|
July 11, 2020
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
Zhexuan Wang, Enxin Wang, Wei Bai, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Journal of Hepatology
|
January 21, 2019
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
Qiuhe Wang, Dongdong Xia, Wei Bai, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Oncology Research
|
September 28, 2019
Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres<sup>®</sup> in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres<sup>®</sup> Transarterial Chemoembolization in Liver Cancer (CTILC) Study
Junhui Sun, Guanhui Zhou, Xiaoxi Xie, et al.
Liver Cancer
|
March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Zhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
Medicine
|
March 21, 2020
Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study
Jun Luo, Jiaping Zheng, Changsheng Shi, et al.
Oncology Research
|
December 21, 2019
The Comprehensive Analysis of Efficacy and Safety of CalliSpheres<sup>®</sup> Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study
Zhiyi Peng, Guohong Cao, Qinming Hou, et al.
Translational Cancer Research
|
February 4, 2022
Efficacy and safety of CalliSpheres<sup>®</sup> drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study
Xia Wu, Shihong Ying, Jing Huang, et al.
Frontiers in Oncology
|
August 19, 2022
A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Hong Yang, Lin Wang, Guoliang Shao, et al.
Liver Cancer
|
August 20, 2025
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Yoon Jun Kim, Philippe Merle, Richard S Finn, et al.
Liver Cancer
|
July 11, 2020
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
Zhexuan Wang, Enxin Wang, Wei Bai, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Journal of Hepatology
|
January 21, 2019
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
Qiuhe Wang, Dongdong Xia, Wei Bai, et al.
Page
of 9